Mostafa Faisal, Adjunct Assistant Professor at Alfaisal University, shared Naveen Pemmaraju’s, Professor in the Department of Leukemia at UT MD Anderson Cancer Center, post on X, adding:
“Phase 3 TRANSFORM-1: Adding navitoclax to ruxolitinib improved spleen responses in JAK inhibitor–naïve intermediate-2/high-risk myelofibrosis.
Results: SVR35 at Week 24: 63.2% vs 31.5% (P<0.0001)
Best Response: Best SVR35 anytime: 76.8% vs 44.1%
Molecular Response: ≥20% VAF reduction: 58.5% vs 45.5%, but symptom improvement was similar (TSS: −10.2 vs −11.6).
Safety: Higher grade 3/4 thrombocytopenia (54% vs 19%), neutropenia (40% vs 9%), and diarrhea (42% vs 17%), with cytopenias generally manageable using dose modifications.”
Quoting Naveen Pemmaraju’s post:
“Proud to share our international randomized frontline Myelofibrosis Ph3 TRANSFORM-1 final results | Navitoclax + RUXO | MPNSM just out in Blood Journals Portfolio today!”
Title: TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis
Authors: Naveen Pemmaraju, Adam J. Mead, Tim C.P. Somervaille, Francesca Palandri, Steffen Koschmieder, Robert Delage, Jean-Jacques Kiladjian, Christopher B Benton, Srinivas K Tantravahi, Noa Lavi, Su-Peng Yeh, Maria Teresa Gomez Casares, Emanuele Ammatuna, Andrew Bruce McDonald, Sung-Soo Yoon, Keita Kirito, Timothy Devos, Andrew C Perkins, Atanas Radinoff, Omur Gokmen Sevindik, Andrija Bogdanovic, Rastislav Moskal, Jason G. Harb, Bryan C Murray, Qi Jiang, Avijeet S. Chopra, Elektra J. Papadopoulos, Jalaja Potluri, Francesco Passamonti
Other articles featuring Mostafa Faisal and Naveen Pemmaraju on OncoDaily.